CFM
NUVB icon

Catalyst Funds Management’s Nuvation Bio NUVB Stock Holding History

Catalyst Funds Management’s Portfolio NUVB Stock Details NUVB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-10,600
Closed -$45.5K – 812
2026
Q1 		$45.5K Buy
+10,600
New +$59.1K 0.01% 547
2025
Q4 		– Sell
-94,800
Closed -$351K – 506
2025
Q3 		$351K Buy
+94,800
New +$258K 0.05% 301
2024
Q2 		– Sell
-15,000
Closed -$54.6K – 1466
2024
Q1 		$54.6K Buy
+15,000
New +$28.8K 0.02% 538

Other funds holding NUVB

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
OFM
Omega Fund Management Boston, Massachusetts $186M AUM 155.23% 1-Year Est. Return
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
DFO
Duquesne Family Office New York $5.21B AUM 87.01% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Catalyst Funds Management's NUVB Position: Q2 2026 in Review

Catalyst Funds Management sold out of Nuvation Bio (NUVB) in Q2 2026, closing a stake of 10,600 shares — an estimated $45.5K sold.

Catalyst Funds Management first reported a position in NUVB in Q1 2024 and held it in 3 quarters. The position peaked at $351K in Q3 2025. 244 funds tracked by Wall St. Rank hold NUVB as of Q2 2026.

  • Catalyst Funds Management reported no remaining Nuvation Bio position as of Q2 2026 after selling out during the quarter.
  • Catalyst Funds Management sold 10,600 Nuvation Bio shares in Q2 2026, an estimated $45.5K.
  • Catalyst Funds Management first reported a position in Nuvation Bio in Q1 2024 and held it in 3 quarters.
  • Catalyst Funds Management's Nuvation Bio position peaked at $351K in Q3 2025.
  • 244 funds tracked by Wall St. Rank held Nuvation Bio as of Q2 2026.

Based on Catalyst Funds Management's 13F filing for Q2 2026, filed 10 Aug 2026.